Slide 1: Q3 2022 Business Update
Q3 2022 Business Update November 8, 2022 NASDAQ:OCGN
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are based on the beliefs and assumptions of Ocugen, Inc. and on information currently available to management. All statements contained i
Slide 3: Q3 2022 Accomplishments — Progress Toward Long-Term Strategy
Q3 2022 Accomplishments —Progress Toward Long-Term Strategy OCU500 Licensing Agreement for a Mucosal COVID-19 Vaccine • Acquired rights to Develop, Manufacture and Commercialize in U.S., Europe, and Japan • An important addition to Ocugen’s COVID-19 vaccine portfolio • Represents a potential univers
Slide 4: OCU500: Mucosal Vaccine
OCU500: Mucosal Vaccine • Potential to generate rapid local immunity in the nose, mouth, upper airways, and lungs -where SARS- CoV-2 enters and infects the body • Generates neutralizing IgG, mucosal IgA, and T cell responses to help reduce transmission rate • Mucosal immunity has been demonstrated a
Slide 5: COVAXIN (BBV152)
COVAXIN™(BBV152) Enrollment completed for Phase 2/3 immuno-bridging and broadening clinical trial • No safety concerns identified to date • Topline data expected in early 2023 • Successfully completed demonstration batch as part of the technology transfer 5
Slide 6: OCU400 DSMB Recommended Proceeding to Enroll Subjects in Cohort 3
OCU400 Data and Safety Monitoring Board Recommended Proceeding to Enroll Subjects in Cohort 3 • The Company expects to complete Cohort 3 enrollment by the end of 2022 • Current study will also begin enrolling patients with Leber congenital amaurosis (LCA) CEP290 mutations o LCA is a rare eye disease
Slide 7: OCU410 & OCU410ST
OCU410 & OCU410ST Utilizes AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene OCU410 • Being developed for the treatment of dry AMD • Successfully completed cGMP manufacturing in support of clinical trials • Currently conducting IND-enabling toxicology st
Slide 8: OCU200
OCU200 • Novel Transferrin-Tumstatin fusion protein • Currently executing IND-enabling studies • Designed to treat severely sight-threatening diseases like Diabetic Macular Edema (DME), diabetic retinopathy, and wet AMD • Planning to submit an IND application in Q1 2023 to initiate Phase 1 clinical
Slide 9: NeoCart - Ocugen's Expansion into Regenerative Cell Therapy
NeoCart® - Ocugen’s Expansion into Regenerative Cell Therapy • NeoCart® shows potential to accelerate healing and reduce pain, rebuilding damaged knee cartilage and limiting the progression towards osteoarthritis • Working with the FDA to finalize the Phase 3 clinical trial protocol necessary to adv
Slide 10: We're Here to Make an Impact Through Courageous Innovation
We’re Here t o Make an Impact Through 10 Courageous Innovation
Slide 11: Financial Update
Financial Update ocugen.
Slide 12: Financial Update: Statement of Operations and Balance Sheet Data
Financial Update Statement of Operations Three months ended September 30, 2022 2021 Research and development expense $15.6 $6.3 General and administrative expense 7.5 4.5 Other income (expense), net 1.2 — Net loss $(21.9) $(10.8) Net loss per share of common stock — basic and diluted $(0.10) $(0.05)
Slide 13: Questions & Answers
Questions & Answers ocugen.
Slide 14: Thank you!
November 8, 2022 NASDAQ:OCGN Thank you! 14